Author
Senior reporter
Covid-19: Big pharma to the rescue
As the world watches and waits for a vaccine, we ask what IR is like under the pandemic spotlight
‘The scrutiny is extraordinarily high,’ says Nick Mazing, director of research at Sentieo, talking about the media and market focus on pharmaceuticals and biotech firms involved in the fight against Covid-19. ‘And it’s not just scrutiny. It is interference.’
As
Content Preview
to continue reading
Subscribe
- IR Essentials - print editions
- Unlimited Articles online
- Newsletter
- Award Winning IR reports
- Strategy guides
- White papers
from$995*
Case studies
As fears of a recession mount, US executives are increasingly addressing the topic on their conference calls with investors and analysts. The number...Read more
Investors in The Restaurant Group, which owns the Wagamama chain, have been warned by a corporate governance research service that they need to be...Read more
Last year, Link Asset Management was nominated for several prizes at the IR Magazine Awards – China 2021, ultimately winning for best annual report...Read more
Customers spent more buying stuff from companies that engaged in corporate social responsibility (CSR) than those that didn’t – as long as those do-...Read more
